Regeneron (REGN) Up 30 Points On Allergan Delays For Vision Loss Drug 

As news came out from an Allergan (AGN $98.5) off 12%, conference call that their vision loss drug would be delayed, Regeneron shares soared 14%. Regeneron now has a market cap of $24B with a PE of 35.85 and a Price to Sales in the 16 range. 2013 Revenues are estimated at $1.9B.

Regeneron was added to the Rayno Life Science Portfolio in March of 2009 at a Price of $17.50 and is the single biggest winner.

In other action today many of our Life Science stocks were in the red with significant profit taking in: AMRI, ASTX, IMGN, PCYC,  and SGEN. There appears to be significant distribution of stock today noting that many  high flyers are down.

%d bloggers like this: